[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maria Cecilia Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":179},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,69,93,115,137,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100638150","cardiovascular-prevention-supported-by-digital-technology-comparison-with-the-traditional-model-100638150",false,"NCT07608926","Cardiovascular Prevention Supported by Digital Technology: Comparison With the Traditional Model","DIGITAL PREV","Inclusion Criteria:\n\n* Age between 40 and 75 years\n* hypertension\n* hyperglycaemia\n* type 2 diabetes not requiring insulin therapy\n* dyslipidaemia\n* active smoking\n* overweight\u002Fgrade I obesity\n* Willingness to participate in follow-up visits over 24 months\n\nExclusion Criteria:\n\n* previous myocardial infarction\n* stroke\n* transient ischemic attack\n* coronary artery diseas\n* peripheral arterial occlusive disease\n* heart failure\n* Type 1 or type 2 diabetes mellitus on insulin therapy\n* Advanced chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Active cancer disease\n* Severe obesity\n* Inability to use digital tools\n* Pregnancy","ALL","40 Years","75 Years",{"count":20,"type":21},144,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cardiovascular diseases represent one of the leading causes of morbidity and mortality worldwide. Prevention in patients at cardiovascular risk is essential to reduce the incidence of cardiovascular events and slow the progression of risk.\n\nThis study aims to evaluate the effectiveness and feasibility of a cardiovascular prevention pathway delivered remotely through a digital application, comparing it with a traditional in-person care pathway.",[27],"Cardiovascular (CV) Risk",[29,30],"Cardiovascular risk factors","Prevention","RECRUITING","2026-05-19",{"date":34,"type":35},"2026-05-27","ACTUAL",{"date":37,"type":35},"2025-05-28",{"date":39,"type":21},"2028-06",{"name":41,"class":42},"Maria Cecilia Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100640911","local-and-systemic-macrophage-activation-in-coronary-and-peripheral-artery-disease-100640911","NCT07588295","Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease","Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease: the LAST-COP Study","Inclusion Criteria:\n\n* Patients with chronic coronary artery disease;\n* Patients with no-ST elevation acute coronary syndrome;\n* Patients with chronic claudication (Rutherford II-III)\n* Patients with critical limb ischemia (Rutherford IV-V).\n\nExclusion Criteria:\n\n* Severe renal dysfunction\n* Severe valve disease\n* Advanced heart failure\n* Advanced liver disease\n* Chronic inflammatory or autoimmune disease\n* Use of antinflammatory drugs\n* Acute infection\n* Recent surgical procedures","18 Years",{"count":53,"type":21},60,[24],"Numerous clinical studies have highlighted the role of macrophages in the destabilization of coronary lesions; however, there is limited literature on the relationship between circulating monocytes and intraplaque macrophages.\n\nThis study aims to evaluate and compare the presence of macrophages and their subsequent activation within coronary and peripheral atherosclerotic lesions, and to correlate these findings with the distribution of circulating monocyte subpopulations.",[57,58,59,60],"Stable Coronary Artery Disease","Acute Coronary Syndromes","Critical Limb Ischemia","Intermittent Claudication","2026-05-11",{"date":63,"type":35},"2026-05-14",{"date":65,"type":35},"2024-03-18",{"date":67,"type":21},"2026-12",{"name":41,"class":42},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100602588","comparing-measurements-of-the-aortic-valve-taken-during-surgery-with-those-obtained-before-surgery-using-computed-tomography-scans-in-patients-undergoing-surgical-aortic-valve-replacement-100602588","NCT07125469","Comparing Measurements of the Aortic Valve Taken During Surgery With Those Obtained Before Surgery Using Computed Tomography Scans, in Patients Undergoing Surgical Aortic Valve Replacement","Intraoperative Assessment Versus Preoperative Multidetector Computed Tomography (MDCT) for Aortic Valve Annular Sizing in Surgical Aortic Valve Replacement (SAVR)\"","SAVR-CT-AVA","Inclusion Criteria:\n\nPatient age 18 years or older\n\nAll patients with isolated severe Aortic Stenosis (AS) considered eligible for Surgical Aortic Valve Replacement (SAVR) according to the current 2023 European Society of Cardiology\u002FEuropean Association for Cardio-Thoracic Surgery (ESC\u002FEACTS) guidelines for management of Valvular Heart Disease (reference 8) will be enrolled.\n\nPatient is willing to comply with study procedures and is available to return to the center for follow-up visits.\n\nInformed consent documentation signed and dated confirming that the patient has been adequately informed of all aspects related to his\u002Fher participation in the clinical study and is willing to participate.\n\nExclusion Criteria:\n\nBicuspid aortic valve anatomy Moderate to severe aortic valve regurgitation Multivalvular disease Redo Surgical Aortic Valve Replacement Ascending aorta aneurysm Aortic root enlargement Chronic Kidney Disease with estimated Glomerular Filtration Rate less than 30 milliliters per minute Body Mass Index greater than 30 kilograms per square meter Inadequate Multidetector Computed Tomography images",{"count":78,"type":21},82,[24],"This study aims to understand why there may be differences between the measurements of the aortic valve taken before and during surgery. Specifically, it will compare the valve size suggested by a CT scan (Computed Tomography) with the size measured during the operation using surgical tools. This will help determine which method is more accurate for selecting the right valve size in patients undergoing SAVR (Surgical Aortic Valve Replacement ).",[82],"Valvular Heart Disease",[84],"valve size, Surgical Aortic Valve Replacement","2026-05-04",{"date":87,"type":35},"2026-05-08",{"date":89,"type":35},"2025-06-25",{"date":91,"type":21},"2026-12-31",{"name":41,"class":42},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":43},"100603060","effects-of-bariatric-surgery-on-cardiovascular-risk-profile-in-relation-to-inflammatory-parameters-endothelial-phenotyping-and-analysis-of-the-cross-talk-between-adipose-tissue-and-endothelium-100603060","NCT07131605","Effects of Bariatric Surgery on Cardiovascular Risk Profile in Relation to Inflammatory Parameters: Endothelial Phenotyping and Analysis of the Cross-talk Between Adipose Tissue and Endothelium","BARIHEART","Inclusion Criteria:\n\nAdults (≥ 18 years old); Patients with obesity (Body Mass Index ≥ 30 kg\u002Fm²); Patients scheduled to undergo bariatric surgery via mini-gastric bypass or sleeve gastrectomy; Patients able to give their consent and to provide signed and dated informed consent for the processing of personal data; Willingness to attend follow-up visits and undergo all assessments required by the study protocol.\n\nExclusion Criteria:\n\nActive systemic inflammatory diseases (e.g., chronic inflammatory bowel diseases, chronic rheumatologic diseases); Acute or chronic infections Severe anemia or coagulation disorders; Moderate to severe chronic kidney disease; Active malignancies.",{"count":101,"type":21},85,[24],"This research project aims to study how obesity affects the heart and metabolism, and how these effects change after significant weight loss following bariatric surgery. In particular, we want to look at how blood vessels and fat tissue function in people with obesity, to detect early signs of vascular problems and understand how fat tissue communicates with blood vessels.\n\nOur main idea is that obesity disrupts the normal function of blood vessels, partly due to substances released by fat tissue and changes in gut bacteria. We believe that 6 and 12 months after surgery - with proper weight loss - these problems will gradually improve. We expect to see better blood vessel function and lower levels of inflammation and fat-related substances in the blood, which could significantly reduce the overall risk of heart disease.",[105],"Obesity (Disorder)",[107,108],"obesity","cardiovascular risk",{"date":87,"type":35},{"date":111,"type":35},"2024-11-11",{"date":113,"type":21},"2026-11-11",{"name":41,"class":42},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":43},"100488676","brugada-syndrome-substrate-characterization-and-ablation-100488676","NCT05643209","Brugada Syndrome Substrate Characterization and Ablation","Brugada Syndrome Substrate Characterization and Ablation: Insights From ECG BrS Type I Pattern, Novel Prognostic Index dST-Tiso and High Density Mapping","UNCOVERBrS","Inclusion Criteria:\n\n1. Symptomatic patients diagnosed with BrS-ECG pattern of types 1 and 2, both spontaneous and arising after Ajmaline tests, already implanted with an ICD.\n\n   Symptomatic patients are defined as those who present ≥1 documented episode of VT \u002F VF in the 12 months prior to enrollment.\n2. Patients eligible for ablation with 3D high-density mapping system in accordance with national guidelines, IFU and according to medical decision;\n3. Adult patients able to provide written informed consent\n\nExclusion Criteria:\n\n1. Patients unable to provide written informed consent;\n2. Patients unable to guarantee their presence at future FU visits;\n3. Patients who, according to medical judgment, have a life expectancy of less than 12 months;\n4. Patients who have undergone cardiac ablation in the 90 days prior to enrollment.\n5. Patients who have had adverse events that have not been resolved after any invasive procedure;\n6. Women potentially pregnant or planning to become pregnant.",{"count":124,"type":21},20,[24],"Independent, single center, prospective study, to evaluate the efficacy, in consecutive BrS patients undergoing catheter ablation, at medium-long term follow-up after epicardial substrate homogenization. The target area is defined collecting signals using high density and high resolution mapping with equi-spaced electrode array. The ablation of abnormal fragmented prolonged low-frequency ventricular electrograms is performed by contact force catheter.",[128],"Brugada Syndrome","2025-08-12",{"date":131,"type":35},"2025-08-15",{"date":133,"type":35},"2023-02-01",{"date":135,"type":21},"2026-06-30",{"name":41,"class":42},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":43},"100543950","the-cardiovascular-prevention-program-100543950","NCT06362538","The Cardiovascular Prevention Program","Cardiovascular Prevention Program at Maria Cecilia Hospital","Inclusion Criteria:\n\n* primary prevention: age ≥ 30 years with a negative history of cardiovascular events\n* secondary prevention: age ≥ 30 years with a negative history of cardiovascular events\n\nExclusion Criteria:\n\n* severe obesity\n* high-grade renal failure\n* severe and\u002For dialysis\n* oncological disease in active phase\n* pregnancy","30 Years",{"count":146,"type":21},150,[24],"Cardiovascular diseases represent one of the main public health problems being the leading cause of morbidity, disability and mortality. In recent decades, the global prevalence and cardiovascular disease mortality has increased, with 23.6 million annual deaths expected by 2030. In Europe, mortality per year is equal to 2.2 million women and 1.9 million men, representing 47% and 37% of all deaths respectively. In Italy, the situation in terms of deaths due to cardiovascular diseases it is in line with the world ranking and European, being responsible for 44% of all deaths. The only interventional or pharmacological approach is neither effective nor sustainable. The most deaths from cardiovascular diseases are due to atherothrombotic events, which are attributable to a series of risk factors, most of which are modifiable. Turns out itself as a targeted action on these factors with the aim of safeguarding the state of health cardiovascular, may represent the best applicable strategy. It is therefore necessary structure and activate prevention programs aimed at the general population and groups of subjects at higher risk.",[150],"Cardiovascular Prevention","2024-08-27",{"date":153,"type":35},"2024-08-28",{"date":155,"type":35},"2024-05-13",{"date":157,"type":21},"2027-04-15",{"name":41,"class":42},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100470867","study-of-role-of-blood-microvescicles-and-exosomes-in-patients-with-graft-occlusion-after-aortocoronary-bypass-surgery-100470867","NCT05411445","Study of Role of Blood Microvescicles and Exosomes in Patients With Graft Occlusion After Aortocoronary Bypass Surgery","MVBYPASS","Inclusion Criteria:\n\n* between the ages of 40 and 80\n* Ejection fraction\\> 30%\n* coronary artery bypass surgery\n* informed consent\n* Willingness to carry out the follow-up visits and the assessments required by the protocol\n\nExclusion Criteria:\n\n* emergency intervention\n* changes in liver or kidney function\n* changes in coagulation factors\n* associated interventions (valve replacement, carotid endarterectomy)","80 Years",{"count":168,"type":21},300,"OBSERVATIONAL","Coronary artery bypass graft (CABG) surgery is still the standard treatment of coronary revascularization for patients with severe coronary artery disease (CAD). Graft patency, together with completeness of revascularization, is a major determinant of long-term outcome following CABG. The surgical procedure elicits a persistent systemic inflammatory response associated with the activation of the hemostatic system leading to perturbation of endothelial and vascular function and activation of platelets and leukocytes. All of these events are the main players responsible for the early and late graft failure in a significant percentage of patients.",[172],"Coronary Artery Bypass Surgery",{"date":153,"type":35},{"date":175,"type":35},"2022-06-01",{"date":177,"type":21},"2025-09-01",{"name":41,"class":42},""]